ADRs Close Lower; Aslan Pharmaceuticals Declines 17% morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
The growing demand in Australia Oncology market is projected to reach US$ 420.4 million by 2030, with an annual growth rate of 9%Wilmington, Delaware, Oct. 29, 2023 (GLOBE NEWSWIRE) Australia Oncology Market value is estimated at US$ 230 million in 2023 and is expected to grow at a significant CAGR of over 9% over the forecast period of 2023-2030, according to the latest market report by RationalStat Market Definition, Market Scope, and Report Overview The oncology market is the segment of th
(2023-10-24 | NDAQ:ASLN) ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
Oncology Market Size to Register USD 556 35 Billion Globally, by 2030, at 7 80% CAGR Growth | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) released topline data from its TREK-AD Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (AD). Eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo with statistical significance in three dosing arms: 600mg dosed once every four weeks (600mg Q4W), which was numerically the best-performing arm, 400mg dosed once ev